<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Diagnosis of nontuberculous mycobacterial infections of the lungs
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Diagnosis of nontuberculous mycobacterial infections of the lungs
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Diagnosis of nontuberculous mycobacterial infections of the lungs
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David E Griffith, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            C Fordham von Reyn, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Dec 06, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The possible presence of nontuberculous mycobacterial (NTM) lung disease often arises clinically when NTM are identified on sputum culture from a patient under evaluation for tuberculosis. The laboratory findings used to confirm the diagnosis of NTM infection in this setting will be reviewed here. The epidemiology, pathogenesis, and treatment of NTM are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">
          "Epidemiology of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5345.html" rel="external">
          "Pathogenesis of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1929151743">
         <span class="h1">
          CLINICAL FEATURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         NTM infections of the lungs often occur in the context of preexisting lung disease, especially chronic obstructive pulmonary disease (COPD), bronchiectasis, pneumoconiosis, cystic fibrosis, and previous tuberculosis [
         <a href="#rid1">
          1-4
         </a>
         ]. As a result, the clinical manifestations of NTM lung disease are often similar to those of the underlying disease. These include cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, and chest discomfort. These same symptoms are also present in patients with NTM lung disease who do not have preexisting pulmonary disease. (See
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CHEST IMAGING
         </span>
         <span class="headingEndMark">
          —
         </span>
         The radiographic findings of NTM lung disease are variable, depending in part upon the species. Findings consistent with NTM pulmonary infection on chest radiograph or high-resolution computed tomography scan include infiltrates (usually nodular or reticulonodular), cavities, multifocal bronchiectasis, and/or multiple small nodules. (See
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections"
         </a>
         .)
        </p>
        <p>
         The radiographic pattern of disease can usually be separated into predominantly cavitary versus nodular/bronchiectatic. Some generalizations can be made:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cavitary disease in the upper lung zones, similar to pulmonary tuberculosis, is seen in approximately 90 percent of patients with
         <em>
          Mycobacterium kansasii
         </em>
         infection and perhaps 50 percent of those with
         <em>
          Mycobacterium avium
         </em>
         complex (MAC) infection.
         <em>
          Mycobacterium xenopi
         </em>
         lung infection is also frequently associated with cavities. The cavities caused by these organisms tend to have thinner walls and less surrounding parenchymal opacity than those caused by
         <em>
          Mycobacterium tuberculosis
         </em>
         [
         <a href="#rid5">
          5,6
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least 50 percent of patients with MAC lung disease have radiographic abnormalities characterized by nodules associated with bronchiectasis or nodular/bronchiectatic disease. The nodules and bronchiectasis are usually present within the same lobe and occur most frequently in the right middle lobe and lingula [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         One study, for example, evaluated 100 patients with bronchiectasis, 24 of whom also had multiple pulmonary nodules [
         <a href="#rid8">
          8
         </a>
         ]. Among the patients in whom sputum cultures were obtained, a positive culture for MAC was much more likely in those with pulmonary nodules than in those without pulmonary nodules (53 versus 4 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         High-resolution CT scans of the chest are especially helpful for diagnosing this pattern of MAC lung disease as bronchiectasis and small nodules may not be easily discernible on plain chest radiograph [
         <a href="#rid9">
          9
         </a>
         ]. The nodular/bronchiectatic radiographic pattern can also be seen with other NTM pathogens, including
         <em>
          Mycobacterium abscessus
         </em>
         ,
         <em>
          Mycobacterium simiae
         </em>
         , and
         <em>
          M. kansasii
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Solitary nodules and dense consolidation have also been described.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Pleural effusions are uncommon, but reactive pleural thickening is frequently seen.
        </p>
        <p>
        </p>
        <p>
         The relative percentage of patients with NTM infection who have cavitary versus non-cavitary disease depends on both the pathogen isolated and the geographic origin of the patient. As an example, patients in Northern Europe appear more likely to have cavitary NTM lung disease compared with patients in North America [
         <a href="#rid10">
          10
         </a>
         ]. The reasons for this disparity are uncertain, but it may be related to the relatively high prevalence of
         <em>
          M. xenopi
         </em>
         lung disease in Northern Europe and the relatively decreasing prevalence of
         <em>
          M. kansasii
         </em>
         in North America.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h1">
          MICROBIOLOGIC EVALUATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the lack of diagnostic specificity of chest radiography, the diagnosis of NTM lung disease requires microbiologic confirmation  (
         <a class="graphic graphic_table graphicRef61404" href="/z/d/graphic/61404.html" rel="external">
          table 1
         </a>
         ). The management of patients with NTM lung disease requires access to a reliable mycobacteriology laboratory with the capability to perform accurate identification of NTM species and appropriate in vitro drug susceptibility testing. This level of laboratory support is essential.
        </p>
        <p class="headingAnchor" id="H3442553383">
         <span class="h2">
          Sputum testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The possible presence of NTM infection should be considered in a patient with a chronic pulmonary infiltrate with or without a cavity and persistence of associated symptoms, such as cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, or chest discomfort. When suspected, respiratory specimens should be submitted for microbiologic testing for NTM.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Collection of respiratory specimens
         </strong>
         – The diagnostic evaluation should consist of smear and culture of at least three separate expectorated sputum specimens obtained in the morning. For patients who have difficulty providing expectorated sputum specimens, sputum induction with hypertonic
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         is usually effective.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the etiology of the patient's symptoms remains uncertain (eg, sputum cultures are uninformative or sputum specimens cannot be obtained) and the infiltrate persists, bronchoscopy with bronchoalveolar lavage (BAL) and/or transbronchial biopsies should be performed. However, for most patients, sputum induction provides adequate specimens for acid-fast bacilli (AFB) analysis.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiologic testing
         </strong>
         – Sputum should be submitted for AFB smear (microscopy) and culture. Sputum sent for culture of NTM must first be chemically decontaminated to eliminate common bacteria and fungi that would overwhelm the culture. (See
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria", section on 'Culture'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For patients at risk for tuberculosis or with a radiographic appearance consistent with pulmonary tuberculosis, sputum nucleic acid amplification testing (NAAT) for tuberculosis should also be done. Clinicians should have a low threshold for ordering NAAT to avoid missing active tuberculosis with atypical radiographic findings. (See
         <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">
          "Diagnosis of pulmonary tuberculosis in adults", section on 'Molecular testing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Highly accurate nucleic acid probes (Accuprobe, GenProbe, Inc) are also commercially available that can identify
         <em>
          M. avium
         </em>
         complex (MAC) isolates within one day after recognizable growth is evident, a technique currently used by most reference laboratories. A similar nucleic acid probe is also available for the identification of
         <em>
          M. kansasii
         </em>
         and
         <em>
          Mycobacterium gordonae
         </em>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sputum culture interpretation
         </strong>
         – Positive sputum cultures for NTM must be interpreted cautiously, since NTM isolation does not always indicate NTM lung disease. These organisms have variable virulence and can be recovered from the respiratory tract without causing progressive infection (ie, they can cause transient infection). In addition, NTM are common in the natural environment and may contaminate laboratory specimens. Tap water (liquid or frozen) especially may contain NTM and contaminate clinical and laboratory specimens. The presence of consistent symptoms cannot necessarily distinguish between transient infection or contamination and true infection, as many patients with suspected NTM have underlying lung disease that causes similar symptomatology. Thus, diagnostic criteria require that more than one expectorated sputum specimen is culture positive; critical assessment over time is often necessary. (See
         <a class="local">
          'Diagnostic criteria'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Some studies suggest that time to positive sputum culture detection could help discriminate NTM lung disease from transient infection or contamination. It has been theorized that a heavier mycobacterial burden in the specimen (which may be more likely associated with lung disease) results in earlier detection. In a retrospective study of 125 patients who had NTM isolated on sputum culture, a shorter time to positive sputum culture was associated with NTM lung disease, for which 65 percent of the study population met diagnostic criteria v [
         <a href="#rid11">
          11
         </a>
         ]. The median time to culture positivity was 12 days; a threshold of 10 days or less was associated with NTM lung disease, AFB smear positivity, and ultimate treatment initiation within three to six months.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          DIAGNOSTIC CRITERIA
         </span>
         <span class="headingEndMark">
          —
         </span>
         In an attempt to address the difficulties in diagnosis (eg, distinguishing transient infection, colonization, or contamination from true infection), the American Thoracic Society (ATS), European Respiratory Society (ERS), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), and Infectious Diseases Society of America (IDSA) jointly endorse specific criteria for the diagnosis of NTM lung disease  (
         <a class="graphic graphic_table graphicRef61404" href="/z/d/graphic/61404.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid4">
          4,12
         </a>
         ]:
        </p>
        <p>
         The diagnostic criteria consist of:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical and radiographic criteria:
         </strong>
         Consistent symptoms with evidence of pulmonary disease on imaging studies and exclusion of other processes such as fungal disease, malignancy, and tuberculosis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <strong>
          PLUS
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiologic criteria:
         </strong>
         These are findings that support NTM clinical infection over colonization or transient infection and include one of the following:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive cultures with the same NTM species from at least two separate expectorated sputum samples (regardless of acid-fast bacilli [AFB] smear result)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Positive culture result from at least one bronchial wash or lavage (regardless of AFB smear result)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transbronchial or other lung biopsy with mycobacterial histopathologic features (granulomatous inflammation or AFB) and positive culture for NTM
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Biopsy showing mycobacterial histopathologic features (granulomatous inflammation or AFB) and one or more sputum or bronchial washings that are culture positive for NTM
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A positive culture from pleural fluid or any other normally sterile extrapulmonary site
        </p>
        <p>
        </p>
        <p>
         Isolation of
         <em>
          M. gordonae
         </em>
         ,
         <em>
          M. mucogenicum
         </em>
         ,
         <em>
          M. nonchromogenicum
         </em>
         ,
         <em>
          M. haemophilum
         </em>
         ,
         <em>
          M. flavescens
         </em>
         ,
         <em>
          M. gastri
         </em>
         ,
         <em>
          M. terrae
         </em>
         , or
         <em>
          M. triviale
         </em>
         indicates probable colonization or contamination. These organisms are generally not pathogenic for humans except in the context of severe cellular immunodeficiency, such as end-stage HIV.
         <em>
          M. fortuitum
         </em>
         is relatively frequently isolated but rarely associated with significant NTM lung disease. Expert consultation should be obtained when NTM are recovered that are either infrequently encountered or that usually represent environmental contamination. Making a diagnosis of NTM infection may not necessitate the initiation of treatment. (See
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p>
         Isolation of NTM in symptomatic patients, regardless of whether the above 2020 ATS/IDSA/ERS/ESCMID criteria are met, may itself be a marker for poor prognosis [
         <a href="#rid12">
          12
         </a>
         ]. In a retrospective review of patients with at least one positive culture for NTM (predominantly from pulmonary specimens), four-year mortality rates were high and not significantly different among the 61 patients who met and the 59 patients who did not meet ATS/IDSA criteria for NTM infection (28 versus 41 percent mortality); a similar percentage of the patients who were treated for NTM did and did not meet criteria [
         <a href="#rid13">
          13
         </a>
         ]. Prognosis was most related to the severity of underlying diseases, which was greater among patients who did not meet criteria. However, determining the prognostic impact of the current diagnostic guidelines is complicated, and the diagnostic criteria remain useful for determining which patients are likely to have significant NTM lung disease and should be considered candidates for therapy.
        </p>
        <p class="headingAnchor" id="H3022034151">
         <span class="h1">
          INVESTIGATIONAL TESTS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Skin tests
         </strong>
         – Species-specific skin test antigens may show considerable cross reactivity and are not commercially available or approved for diagnostic purposes. However, epidemiologic and laboratory studies with well-characterized antigens have shown that dual skin testing with tuberculosis versus NTM-derived tuberculins can discriminate between prior NTM and prior tuberculosis [
         <a href="#rid14">
          14-18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Serodiagnosis/anti-GPL-core IgA antibody
         </strong>
         – The glycopeptidolipid (GPL) core is a cell wall component of
         <em>
          M. avium, M. intracellulare,
         </em>
         and rapidly growing mycobacteria (including
         <em>
          M. abscessus
         </em>
         ) [
         <a href="#rid19">
          19
         </a>
         ]. Other mycobacterial species lack this core component. Emerging data suggest that detection of anti-GPL-core IgA antibody may be a useful tool for diagnosis of MAC or
         <em>
          M. abscessus
         </em>
         lung disease (eg, to meet microbiologic criteria in patients with a single positive sputum culture). Interpretation may be difficult in the setting of MAC and
         <em>
          M. abscessus
         </em>
         co-isolation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Several studies have indicated that anti-GPL-core IgA antibody levels are higher in patients who meet diagnostic criteria for MAC or M. abscessus lung disease than in those without [
         <a href="#rid19">
          19-21
         </a>
         ]. In a meta-analysis of 16 studies that included 1098 subjects with clinically diagnosed MAC lung disease and 2270 controls, the sensitivity and specificity of the anti-GPL-core IgA antibody at a cutoff value of 0.7 units/mL were 70 and 91 percent [
         <a href="#rid19">
          19
         </a>
         ]. Another study suggested that a cutoff value of 0.3 units/mL resulted in the best combination of sensitivity and specificity (70 and 94 percent) [
         <a href="#rid22">
          22
         </a>
         ]. Studies also suggest that the antibody level declines with treatment, suggesting that they may reflect disease activity [
         <a href="#rid19">
          19,20
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2944713356">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/113062.html" rel="external">
          "Society guideline links: Nontuberculous mycobacteria"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1633801088">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical features
         </strong>
         – Nontuberculous mycobacterial (NTM) infections of the lungs often occur in the context of preexisting lung disease, especially chronic obstructive pulmonary disease (COPD), bronchiectasis, pneumoconiosis, cystic fibrosis, and previous tuberculosis. The clinical manifestations of NTM lung disease are often similar to those of the underlying disease. These include cough, fatigue, malaise, fever, weight loss, dyspnea, hemoptysis, and chest discomfort. These same symptoms are also present in patients with NTM lung disease who do not have preexisting pulmonary disease. (See
         <a class="local">
          'Clinical features'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Imaging findings
         </strong>
         – The radiographic findings of nontuberculous mycobacterial (NTM) lung disease are variable, depending in part upon the species. Findings consistent with NTM pulmonary infection on chest radiograph or high-resolution computed tomography scan include infiltrates (usually nodular or reticulonodular), cavities, multifocal bronchiectasis, and/or multiple small nodules. (See
         <a class="local">
          'Chest imaging'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Microbiologic testing
         </strong>
         – Given the lack of diagnostic specificity of chest radiography, the diagnosis of NTM lung disease requires microbiologic confirmation. In patients with a chronic pulmonary infiltrate with or without a cavity and persistent symptoms consistent with NTM, microbiologic evaluation should consist of smear and culture of at least three separate expectorated sputum specimens obtained in the morning. Some patients may require induction with nebulized
         <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">
          saline
         </a>
         to produce sputum. If the etiology of the patient's symptoms remains uncertain and the infiltrate persists, bronchoscopy with bronchoalveolar lavage (BAL) and/or transbronchial biopsies should be performed. (See
         <a class="local">
          'Microbiologic evaluation'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnostic criteria
         </strong>
         – The following criteria are necessary for the diagnosis of NTM lung disease  (
         <a class="graphic graphic_table graphicRef61404" href="/z/d/graphic/61404.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinical and radiographic criteria – Consistent symptoms with evidence of pulmonary disease on imaging studies and exclusion of other processes
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         PLUS
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Microbiologic criteria – Positive cultures with the same NTM species from at least two separate expectorated sputum samples; or a positive culture from at least one bronchoscopic specimen; or a biopsy specimen with granulomatous inflammation or AFB on histologic examination with positive culture from biopsy or respiratory specimen; or a positive culture from a pleural specimen
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Chapman JS. The Atypical Mycobacteria and Human Mycobacteriosis, 16th Ed, Plenum, New York 1977.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yeager H Jr, Raleigh JW. Pulmonary disease due to Mycobacterium intracellulare. Am Rev Respir Dis 1973; 108:547.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Davidson PT. The diagnosis and management of disease caused by M. avium complex, M. kansasii, and other mycobacteria. Clin Chest Med 1989; 10:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Woodring JH, Vandiviere HM. Pulmonary disease caused by nontuberculous mycobacteria. J Thorac Imaging 1990; 5:64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christensen EE, Dietz GW, Ahn CH, et al. Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, and M intracellularis infections. Chest 1981; 80:132.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levin DL. Radiology of pulmonary Mycobacterium avium-intracellulare complex. Clin Chest Med 2002; 23:603.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Swensen SJ, Hartman TE, Williams DE. Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis. Chest 1994; 105:49.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koh WJ, Lee KS, Kwon OJ, et al. Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection. Radiology 2005; 235:282.
          </a>
         </li>
         <li class="breakAll">
          Van Ingen J, Radboud University, 2019, personal communication.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards BD, Brode SK, Mehrabi M, Marras TK. Time to Positive Culture Detection Predicts Mycobacterium avium Pulmonary Disease Severity and Treatment Initiation. Ann Am Thorac Soc 2022; 19:925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis 2020; 71:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kotilainen H, Valtonen V, Tukiainen P, et al. Prognostic value of American Thoracic Society criteria for non-tuberculous mycobacterial disease: a retrospective analysis of 120 cases with four years of follow-up. Scand J Infect Dis 2013; 45:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edwards LB, Acquaviva FA, Livesay VT, et al. An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States. Am Rev Respir Dis 1969; 99:Suppl:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Reyn CF, Green PA, McCormick D, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis. Clin Infect Dis 1994; 19:15.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huebner RE, Schein MF, Cauthen GM, et al. Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses. Am Rev Respir Dis 1992; 145:1160.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Reyn CF, Williams DE, Horsburgh CR Jr, et al. Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis. J Infect Dis 1998; 177:730.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           von Reyn CF, Horsburgh CR, Olivier KN, et al. Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States. Int J Tuberc Lung Dis 2001; 5:1122.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shibata Y, Horita N, Yamamoto M, et al. Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis. Sci Rep 2016; 6:29325.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernandez AG, Brunton AE, Ato M, et al. Use of Anti-Glycopeptidolipid-Core Antibodies Serology for Diagnosis and Monitoring of Mycobacterium avium Complex Pulmonary Disease in the United States. Open Forum Infect Dis 2022; 9:ofac528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kawasaki T, Kitada S, Fukushima K, et al. The Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease by Single Bacterial Isolation Plus Anti-GPL-Core IgA Antibody. Microbiol Spectr 2022; 10:e0140621.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kitada S, Levin A, Hiserote M, et al. Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA. Eur Respir J 2013; 42:454.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 5346 Version 15.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Chapman JS. The Atypical Mycobacteria and Human Mycobacteriosis, 16th Ed, Plenum, New York 1977.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4745250" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pulmonary disease due to Mycobacterium intracellulare.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2673651" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : The diagnosis and management of disease caused by M. avium complex, M. kansasii, and other mycobacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17277290" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2182904" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Pulmonary disease caused by nontuberculous mycobacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6788455" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Initial roentgenographic manifestations of pulmonary Mycobacterium tuberculosis, M kansasii, and M intracellularis infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12370996" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Radiology of pulmonary Mycobacterium avium-intracellulare complex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8275782" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Computed tomographic diagnosis of Mycobacterium avium-intracellulare complex in patients with bronchiectasis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15703315" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15703315" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Bilateral bronchiectasis and bronchiolitis at thin-section CT: diagnostic implications in nontuberculous mycobacterial pulmonary infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34851813" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Time to Positive Culture Detection Predicts Mycobacterium avium Pulmonary Disease Severity and Treatment Initiation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32628747" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23039965" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prognostic value of American Thoracic Society criteria for non-tuberculous mycobacterial disease: a retrospective analysis of 120 cases with four years of follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5767603" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : An atlas of sensitivity to tuberculin, PPD-B, and histoplasmin in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7948519" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Dual skin testing with Mycobacterium avium sensitin and purified protein derivative: an open study of patients with M. avium complex infection or tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1586061" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Evaluation of the clinical usefulness of mycobacterial skin test antigens in adults with pulmonary mycobacterioses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9498455" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Dual skin testing with Mycobacterium avium sensitin and purified protein derivative to discriminate pulmonary disease due to M. avium complex from pulmonary disease due to Mycobacterium tuberculosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11769770" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Skin test reactions to Mycobacterium tuberculosis purified protein derivative and Mycobacterium avium sensitin among health care workers and medical students in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27373718" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36349274" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Use of Anti-Glycopeptidolipid-Core Antibodies Serology for Diagnosis and Monitoring of Mycobacterium avium Complex Pulmonary Disease in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34985326" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The Diagnosis of Nontuberculous Mycobacterial Pulmonary Disease by Single Bacterial Isolation Plus Anti-GPL-Core IgA Antibody.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23100506" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Serodiagnosis of Mycobacterium avium complex pulmonary disease in the USA.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
